July 2023 Archive — Key drug and supplement updates from RedBoxRX

Wondering what we posted in July 2023? This month covered a mix of supplements, common drugs, and newer uses for established medicines. Below you’ll find short, practical takeaways from each article so you can spot what matters fast.

Highlights from July

Centaury: a plant-based dietary supplement that grabbed attention for digestive support and general wellness. Our guide breaks down claimed benefits, likely doses, and safety flags. If you try it, watch for allergic reactions and check interactions with other herbs or meds.

Losartan and COVID-19: early-stage research looked at whether losartan, an ACE receptor blocker used for blood pressure, might change how the virus gets into cells. Findings are preliminary — don’t switch or start blood-pressure meds based on this alone. Talk to your doctor if you’re curious about ongoing trials.

Calcitonin for multiple myeloma: calcitonin can help with bone pain and high blood calcium in certain cancer patients. Our post explains when it’s used, typical effects on pain and calcium levels, and how it fits into broader care alongside chemo or bone-targeting therapies.

Amiloride for ascites: ascites from liver disease causes uncomfortable fluid buildup. Amiloride, a potassium-sparing diuretic, helps reduce abdominal fluid while limiting potassium loss. We cover how it’s used with other diuretics and what to monitor—weight, abdominal girth, kidney function, and potassium.

Velpatasvir’s journey: a look at how velpatasvir moved from lab discovery to an approved Hepatitis C treatment. The story highlights clinical testing, regulatory steps, and real-world impact — useful if you want context on how antiviral drugs reach patients and why combination therapy matters.

Meclizine for seniors: commonly used for vertigo, meclizine can help but often causes drowsiness. Our post gives dosing ideas for older adults, warns about falls and interactions (especially with other sedatives), and suggests safer alternatives when appropriate.

Baricitinib in pemphigus vulgaris: baricitinib, a JAK inhibitor used in rheumatology, shows early promise as a steroid-sparing option for this blistering autoimmune disease. We explain its anti-inflammatory action, potential benefits, and the need for controlled studies before it becomes standard care.

Quick actions for readers

Scan the full posts if you want dosage details, monitoring tips, or study notes. If a drug or supplement mentioned affects you, bring the article to your next clinician visit. Never change prescriptions alone — ask about interactions, lab checks, and safer alternatives when needed.

Want summaries like this every month? Tell us which topics you want covered next — drug safety, supplements, or clinical trial updates — and we’ll focus the next roundup on what helps you most.